Obesity
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Adult: overweight or obesity
Fasting laboratory tests
- Lipid profile
- Fasting plasma glucosePatient over 45 with a BMI > 28 kg/m².
- GGT (Fatty Liver Index, if BMI ≥ 30 kg/m²)if neededBMI ≥ 30 kg/m²: screening for steatosis by the Fatty Liver Index (BMI, waist circumference, GGT, triglycerides) or by abdominal ultrasound; if normal, recheck at 3 to 5 years [2].
- Serum creatinine with GFR (if BMI ≥ 30 kg/m²)if neededBMI ≥ 30 kg/m²: screening for chronic kidney disease (GFR by CKD-EPI and albuminuria) [2], to be repeated every year according to the HAS guide on chronic kidney disease, which lists obesity among the risk factors [3].
- Urine albumin:creatinine ratio (if BMI ≥ 30 kg/m²)if neededBMI ≥ 30 kg/m²: screening for chronic kidney disease (GFR by CKD-EPI and albuminuria) [2], to be repeated every year according to the HAS guide on chronic kidney disease, which lists obesity among the risk factors [3].
- ASTif neededSteatosis on ultrasound: FIB-4 fibrosis score, calculated from age, AST, ALT and platelets [4]; fibrosis excluded if FIB-4 < 1.30, otherwise quantify the fibrosis [2].
- ALTif neededSteatosis on ultrasound: FIB-4 fibrosis score, calculated from age, AST, ALT and platelets [4]; fibrosis excluded if FIB-4 < 1.30, otherwise quantify the fibrosis [2].
- Platelets (if steatosis)if neededSteatosis on ultrasound: FIB-4 fibrosis score, calculated from age, AST, ALT and platelets [4]; fibrosis excluded if FIB-4 < 1.30, otherwise quantify the fibrosis [2].
Do not order
Child and adolescent (up to 15 years): overweight or obesity
- Overweight with no clinical sign of complication and no indication for diabetes screening: no laboratory tests.
Fasting laboratory tests, depending on the context
- Fasting plasma glucose (screening for type 2 diabetes)if neededFrom 10 years of age or the onset of puberty, if overweight or obese, with at least one risk factor: maternal or gestational diabetes, type 2 diabetes in a 1st- or 2nd-degree relative, signs or conditions of insulin resistance (acanthosis nigricans, hypertension, dyslipidaemia, PCOS, low birth weight for gestational age) [12]. Repeat at least every 3 years if normal [12].
- Lipid profileif neededEstablished obesity (BMI ≥ IOTF 30 threshold) with a family history of dyslipidaemia [12].
- ASTif neededEstablished obesity (BMI ≥ IOTF 30 threshold), depending on family history, the trajectory of the BMI curve and the clinical history [12]. Check every 2 to 3 years if normal, especially in adolescence [12].
- ALTif neededEstablished obesity (BMI ≥ IOTF 30 threshold), depending on family history, the trajectory of the BMI curve and the clinical history [12]. Check every 2 to 3 years if normal, especially in adolescence [12].
Also consider
- Early adiposity rebound? Early rebound on the BMI curve: see the page "Early adiposity rebound".
Do not order
- Laboratory tests in a child who is simply overweight, with no sign of complication and no indication for diabetes screening: no test is needed [12].
- TSH, cortisol or other hormonal tests as a routine: HAS (French National Authority for Health) limits the work-up to targeted tests and does not include hormonal tests; it is the examination findings (slowing growth velocity, signs of thyroid dysfunction or hypercortisolism) that guide testing [12].
Sources (12)
- Matta J, Zins M, Feral-Pierssens AL, et al. Prévalence du surpoids, de l'obésité et des facteurs de risque cardio-métaboliques dans la cohorte Constances. Bull Epidémiol Hebd 2016;(35-36):640-6.
- Haute Autorité de santé. Guide du parcours de soins : surpoids et obésité de l'adulte. Validé par le Collège le 11 janvier 2023, mis à jour en février 2024 : chapitre 3.2.2 et tableau 1.
- Haute Autorité de santé. Guide du parcours de soins : maladie rénale chronique de l'adulte (MRC). Juillet 2021, mis à jour en septembre 2023 : chapitre 1 (dépistage).
- Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43(6):1317-25.
- Haute Autorité de santé. Surpoids et obésité de l'adulte : prise en charge médicale de premier recours. Recommandation de bonne pratique, septembre 2011 (fiche de synthèse).
- Conseil scientifique du domaine de la santé (Luxembourg). Prise en charge médico-chirurgicale d'une obésité de l'adulte. Recommandation, 18 octobre 2023 : tableau 3.
- Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. CMAJ 2020;192(31):E875-E891 (lignes directrices canadiennes, recommandation 13).
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 1577 (HbA1c).
- US Preventive Services Task Force. Prediabetes and Type 2 Diabetes: Screening. Final Recommendation Statement, 24 août 2021 (grade B).
- National Institute for Health and Care Excellence (NICE). Overweight and obesity management. NICE guideline NG246, publiée le 14 janvier 2025, mise à jour le 8 janvier 2026 (recommandations 1.9.16, 1.10.13 et 1.12.14).
- National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management. NICE guideline NG203, publiée le 25 août 2021, mise à jour le 24 novembre 2021 (recommandation 1.1.24).
- Haute Autorité de santé. Guide du parcours de soins : surpoids et obésité de l'enfant et de l'adolescent(e). Février 2022, mis à jour en février 2023 : chapitres 2.2 et 2.3.